Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Marinus Pharmaceuticals Inc
61YCurrent price
0.27 EUR
-0.016 EUR (-5.56%)
Last closed
0.3 USD
Company
www.marinuspharma.com
ISIN
US56854Q1013
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
93 091 976 USD
Yield for 12 month
-95.03 %
1Y
3Y
5Y
10Y
15Y
61Y
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Address: 5 Radnor Corporate Center, Radnor, PA, United States, 19087
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.88 USDP/E ratio
–Dividend Yield
–Current Year
+30 989 000 USD
Last Year
+25 478 000 USD
Current Quarter
+8 055 999 USD
Last Quarter
+7 679 000 USD
Current Year
+28 504 000 USD
Last Year
+25 138 000 USD
Current Quarter
+7 180 999 USD
Last Quarter
+6 792 000 USD
Key Figures 61Y
1 year
3 years
5 years
10 years
EBITDA
-128 656 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-57.75 %
PEG Ratio
–
Return On Equity TTM
-2986.55 %
Wall Street Target Price
2.88 USD
Revenue TTM
30 263 000 USD
Book Value
-0.86 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
32.5 %
Dividend Yield
–
Gross Profit TTM
-55 943 000 USD
Earnings per share
-2.66 USD
Diluted Eps TTM
-2.66 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 61Y
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 61Y
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:4
Payout Ratio
–
Last Split Date
23.09.2020
Dividend Date
23.09.2020
Stock Valuation 61Y
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.504
Price Sales TTM
3.0761
Enterprise Value EBITDA
-34.4713
Price Book MRQ
3.1717
Financials 61Y
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 61Y
For 52 weeks
0.26 USD
11.26 USD
50 Day MA
1.53 USD
Shares Short Prior Month
3 221 631
200 Day MA
3.98 USD
Short Ratio
4.89
Shares Short
3 487 427
Short Percent
6.35 %
BeatStart